Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic characterization of functional high-risk multiple myeloma patients.

Blood cancer journal - 31 Jan 2022

Soekojo Cinnie Yentia, Chung Tae-Hoon, Furqan Muhammad Shaheryar, Chng Wee Joo

Abstract excerpt

Multiple myeloma (MM) patients with suboptimal response to induction therapy or early relapse, classified as the functional high-risk (FHR) patients, have been shown to have poor outcomes. We evaluated newly-diagnosed MM patients in the CoMMpass dataset and divided them into three groups: genomic high-risk (GHR) group for patients with t(4;14) or t(14;16) or complete loss of functional TP53 (bi-allelic deletion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma
Share to Aged
Share to Chromosome Aberrations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Damage

Share to Mutation

Share to Prognosis

Share to Risk Assessment

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 35102139
DOI: 10.1038/s41408-021-00576-3
PMCID: PMC8803925

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic characterization of functional high-risk multiple myeloma patients.PMID 35102139Read ↗

Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profilingSemantic proximity Read ↗

Integrative multi-omics identifies high risk Multiple Myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysSemantic proximity Read ↗

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitionsSemantic proximity Read ↗

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy.Semantic proximity Read ↗

Integrative multi-omics identifies high risk Multiple Myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysSemantic proximity Read ↗

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaSemantic proximity Read ↗

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.Semantic proximity Read ↗

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysSemantic proximity Read ↗

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the BedsideSemantic proximity Read ↗

Utilizing Genomics to Identify Novel Immunotherapeutic Targets in Multiple Myeloma High-Risk SubgroupsSemantic proximity Read ↗

DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing.Semantic proximity Read ↗

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.